Eisai's Halaven, GSK's Lupus Drug Among Latest China Approvals
Executive Summary
GSK gains approval of first lupus drug in China, where Benlysta and Eisai’s breast cancer therapy Halaven also receive the green light.
You may also be interested in...
Oncology Dominates As China Drug, Biologic Approvals Surge
China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.